دورية أكاديمية
أعرض في EDS

Potent efficiency of the novel nitazoxanide-loaded nanostructured lipid carriers against experimental cyclosporiasis.

التفاصيل البيبلوغرافية
العنوان: Potent efficiency of the novel nitazoxanide-loaded nanostructured lipid carriers against experimental cyclosporiasis.
المؤلفون: Hagras NA; Department of Medical Laboratory Technology, Faculty of Applied Health Sciences Technology, Pharos University in Alexandria, Alexandria, Egypt., Makled S; Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt., Sheta E; Department of Pathology, Faculty of Medicine, Alexandria University, Alexandria, Egypt., El-Hawary MA; Faculty of Science, Zagazig University, Zagazig, Egypt., Mogahed NMFH; Department of Medical Parasitology, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
المصدر: PLoS neglected tropical diseases [PLoS Negl Trop Dis] 2023 Dec 15; Vol. 17 (12), pp. e0011845. Date of Electronic Publication: 2023 Dec 15 (Print Publication: 2023).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101291488 Publication Model: eCollection Cited Medium: Internet ISSN: 1935-2735 (Electronic) Linking ISSN: 19352727 NLM ISO Abbreviation: PLoS Negl Trop Dis Subsets: MEDLINE
أسماء مطبوعة: Original Publication: San Francisco, CA : Public Library of Science
مواضيع طبية MeSH: Cyclosporiasis*/diagnosis , Cyclosporiasis*/drug therapy , Cyclosporiasis*/parasitology , Cyclospora*, Humans ; Animals ; Mice ; Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use ; Nitro Compounds/therapeutic use ; Oocysts ; Lipids
مستخلص: Cyclosporiasis is a ubiquitous infection caused by an obligate intracellular protozoan parasite known as Cyclospora cayetanensis (C. cayetanensis). The disease is characterized by severe diarrhea which may be regrettably fatal in immunosuppressed patients. The commercially available treatment options have either severe side effects or low efficiency. In the present study, the novel formula of nitazoxanide (NTZ)-loaded nanostructured lipid carriers (NLCs) was assessed for the first time for C. cayetanensis treatment in both immunocompetent and immunosuppressed mice in comparison to commercially available drugs (trimethoprim-sulfamethoxazole (TMP-SMX) and NTZ). Swiss Albino mice were orally infected by 104 sporulated oocysts. The experimental groups were treated with the gold standard TMP-SMX, NTZ, blank NLCs and NTZ-loaded NLCs. The results demonstrated that NTZ-loaded NLCs represented the highest significant parasite percent reduction of (>98% reduction) in both immunocompetent and immunosuppressed mice designating successful tissue penetration and avoiding recurrence of infection at the end of the study. Oocysts treated with NTZ-loaded NLCs demonstrated the most mutilated rapturing morphology via scanning electron microscope examination as well as representing the most profound improvement of the histopathological picture. In conclusion, NTZ-loaded NLCs exhibited the uppermost efficacy in the treatment of cyclosporiasis. The safe nature and the anti-parasitic effect of the novel formulation encourage its use as a powerful treatment for human cyclosporiasis.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright: © 2023 Hagras et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
References: Indian J Med Microbiol. 2004 Apr-Jun;22(2):119-22. (PMID: 17642709)
Emerg Infect Dis. 2014 Oct;20(10):1742-4. (PMID: 25271363)
Int J Clin Pharmacol Ther. 2000 Aug;38(8):387-94. (PMID: 10984012)
Adv Pharm Bull. 2015 Sep;5(3):305-13. (PMID: 26504751)
Microorganisms. 2021 Sep 02;9(9):. (PMID: 34576758)
J Trop Med Hyg. 1995 Oct;98(5):325-9. (PMID: 7563260)
Adv Healthc Mater. 2019 May;8(9):e1801261. (PMID: 30838782)
Drug Deliv Transl Res. 2021 Jun;11(3):1037-1055. (PMID: 32617866)
Exp Parasitol. 2012 Jul;131(3):350-7. (PMID: 22580265)
Nanomedicine. 2016 Jan;12(1):143-61. (PMID: 26410277)
Exp Parasitol. 2019 Sep;204:107717. (PMID: 31228418)
AAPS PharmSciTech. 2014 Dec;15(6):1509-15. (PMID: 25035071)
PLoS Negl Trop Dis. 2022 Mar 16;16(3):e0010268. (PMID: 35294434)
Microorganisms. 2019 Sep 04;7(9):. (PMID: 31487898)
Iran J Parasitol. 2019 Apr-Jun;14(2):240-249. (PMID: 31543912)
Chem Biol Interact. 2020 Dec 1;332:109296. (PMID: 33096056)
Pharmaceutics. 2022 Nov 20;14(11):. (PMID: 36432718)
Nat Rev Mater. 2021;6(12):1078-1094. (PMID: 34394960)
Biomedicines. 2022 Sep 02;10(9):. (PMID: 36140280)
J Parasit Dis. 2022 Mar;46(1):166-177. (PMID: 35299902)
Parasit Vectors. 2015 Aug 07;8:411. (PMID: 26249024)
Clin Infect Dis. 2001 Feb 1;32(3):331-51. (PMID: 11170940)
Ann Intern Med. 2000 Jun 6;132(11):885-8. (PMID: 10836915)
J Infect Dis. 1983 May;147(5):824-8. (PMID: 6842020)
J Clin Pathol. 1996 Jun;49(6):511-2. (PMID: 8763270)
J Antimicrob Chemother. 2000 Jul;46(1):57-60. (PMID: 10882689)
PLoS Negl Trop Dis. 2016 Jul 28;10(7):e0004820. (PMID: 27467505)
Nano Today. 2014 Apr 1;9(2):223-243. (PMID: 25132862)
Folia Parasitol (Praha). 2003 Mar;50(1):19-22. (PMID: 12735719)
Appl Environ Microbiol. 1997 Apr;63(4):1631-2. (PMID: 9097458)
Front Cell Infect Microbiol. 2020 Feb 11;10:43. (PMID: 32117814)
Colloids Surf B Biointerfaces. 2005 Nov 10;45(3-4):167-73. (PMID: 16198092)
Exp Parasitol. 2019 Dec;207:107772. (PMID: 31610183)
Vet Parasitol. 2018 Jan 30;250:7-14. (PMID: 29329627)
Front Chem. 2021 Apr 23;9:580118. (PMID: 33981670)
Lancet Infect Dis. 2019 Jul;19(7):e226-e236. (PMID: 30885589)
Int J Mol Sci. 2022 Apr 11;23(8):. (PMID: 35457059)
Int J Parasitol Drugs Drug Resist. 2021 Dec;17:156-167. (PMID: 34637982)
Am J Respir Crit Care Med. 2005 Dec 15;172(12):1487-90. (PMID: 16151040)
Parasitol Int. 2018 Dec;67(6):666-674. (PMID: 29933042)
Eur J Pharm Sci. 2018 Jan 1;111:526-533. (PMID: 29097304)
J Eukaryot Microbiol. 2002 May-Jun;49(3):201-8. (PMID: 12120985)
Expert Opin Drug Deliv. 2020 Mar;17(3):357-377. (PMID: 32064958)
Exp Parasitol. 2016 Nov;170:28-35. (PMID: 27585500)
Biomacromolecules. 2012 Oct 8;13(10):3253-61. (PMID: 22978827)
PLoS Negl Trop Dis. 2019 Sep 25;13(9):e0007779. (PMID: 31553716)
المشرفين على المادة: SOA12P041N (nitazoxanide)
8064-90-2 (Trimethoprim, Sulfamethoxazole Drug Combination)
0 (Nitro Compounds)
0 (Lipids)
تواريخ الأحداث: Date Created: 20231215 Date Completed: 20240101 Latest Revision: 20240101
رمز التحديث: 20240101
مُعرف محوري في PubMed: PMC10756555
DOI: 10.1371/journal.pntd.0011845
PMID: 38100538
قاعدة البيانات: MEDLINE
الوصف
تدمد:1935-2735
DOI:10.1371/journal.pntd.0011845